Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cingolani, Linda, Barberio, Brigida, Zingone, Fabiana, Ferronato, Antonio, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Melatti, Piera, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, D’Incà, Renata, Savarino, Edoardo Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121777/
https://www.ncbi.nlm.nih.gov/pubmed/33990652
http://dx.doi.org/10.1038/s41598-021-89790-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121777/
https://www.ncbi.nlm.nih.gov/pubmed/33990652
http://dx.doi.org/10.1038/s41598-021-89790-4

Ejemplares similares